From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Rest and allow adjustment time
This is where GHK-Cu, a naturally occurring copper peptide, has gained attention as a non-hormonal, regenerative option for scalp and follicle health
Hence, EBV UTPase may alter the synaptic structure and function in ME/CFS, as well as dysregulate neuronal communication, influencing cognitive processes
What happens after PCAC makes a recommendation, when would compounding actually become legal